Newsfiscal.ai
NeuroSense to Present Clinical and Biomarker Data at NEALS 2026
· Published
Article summary
NeuroSense Therapeutics announced it will present integrated clinical and biomarker findings that are informing the next phase of development for its lead ALS drug candidate, PrimeC, at the 2026 NEALS Consortium Annual Meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…